Publications by authors named "Hong L Tan"

Claim this Profile
A
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.
Monica Florio, Kannan Gunasekaran, Marina Stolina, Xiaodong Li, Ling Liu, Hong Lin Tan

Nat Commun· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
Michael S Ominsky, Chaoyang Li, Xiaodong Li, Hong L Tan, Edward Lee

J Bone Miner Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.
Michael S Ominsky, Marina Stolina, Xiaodong Li, Timothy J Corbin, Franklin J Asuncion, Hong L Tan

J Bone Miner Res· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Paul J Kostenuik, Hung Q Nguyen, James McCabe, Kelly S Warmington, Carol Kurahara, Hong Lin Tan

J Bone Miner Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Sean Morony, Kelly Warmington, Stephen Adamu, Frank Asuncion, Zhaopo Geng, Hong Lin Tan, Colin R Dunstan

Endocrinology· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis